| Gene Variations Point To Why Lung Cancer Drugs Work Better In ...
Last year, a groundbreaking international project found that a group of Japanese patients with advanced non-small cell lung cancer survived longer - and had a higher rate of side effects - than U.S. patients with the same diagnosis, when both groups were given two well-known drugs for the disease.
Now, a follow-up study suggests the reasons appear to lie in subtle variations in certain genes that govern how the body metabolizes chemotherapy drugs. David Gandara, M.D., a University of California, Davis researcher who led the recent Southwest Oncology Group study, presented the results at the American Society of Clinical Oncology annual meeting.
The discovery that Japanese and U.S. patients, matched in age, gender and other respects, had differences in key metabolism-related genes is the latest result from a seven-year collaboration between the Southwest Oncology Group and two clinical trials groups in Japan.
Queen’s new cancer program is well worth the effort
John's Lutheran School and an active coach in basketball, volleyball and track. During what he thought was a routine colonoscopy last August; he was diagnosed with colon cancer.“I was able to teach through the first semester during chemotherapy and radiation, but my first surgery had complications and I was in the hospital for six weeks," said Hauch, 58. “I had liver surgery in May and spent seven days in the hospital."Hauch wants to return to his classroom when school resumes in late August. To ready himself, he's enrolled in the new Cancer Wellness Program at Queen of the Valley Medical Center.“The Cancer Wellness Program has been a two-year project in the making," said Mike Smith, a physical therapist and catalyst for the program. “I've always had an interest in using exercise to relieve pain.
Antwerp radiotherapy centre chooses TomoTherapy cancer treatment ...
Madison, Wis., USA. The new University Radiotherapy Centre of Antwerp has chosen the TomoTherapy HiArt treatment system for providing radiation therapy, and the Centre will serve as a European training facility for TomoTherapy Incorporated (NASDAQ: TTPY). Hospitals participating in the Centre include University Hospital Antwerp and the Antwerp City Hospital Network. Two HiArt treatment systems have been installed on-site at University Hospital Antwerp. Through the University Radiotherapy Center, both member hospitals will use HiArt treatment systems to treat cancer patients with advanced image-guided, intensity-modulated radiation therapy (IG/IMRT). And, through collaboration with TomoTherapy, the machines will also be available for training physicians, hospital staff and TomoTherapy employees while still providing uninterrupted patient care.
|
